Expert Interview
Discussing Ipsen's Phase 3 data from the ELMWOOD study of elafibranor in patients with primary sclerosing cholangitis (PSC)
Ticker(s): IPSEY, IPN.XPARInstitution: MUSC
Professor and Chairman of the Department of Medicine and Hepatology
Treats approximately 50 MASH patients per year, including about 25 with F4 (compensated cirrhosis)
Primary research focus is on establishing evidence-based management strategies for common GI conditions and advancing guideline-directed care through clinical research
How frequently do you manage or consult on cases of primary sclerosing cholangitis (PSC) in your clinical practice?
Added By: sara_adminCan you discuss elafibranor’s mechanism of action and its potential therapeutic role in cholestatic liver diseases like PSC?
Added By: sara_adminBased on the available data, how would you compare elafibranor’s efficacy and safety profile to other investigational therapies or off-label treatments currently used for PSC?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
